The DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index.
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Open accessAbstract
Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOE*ε4 allele conferring an increased risk and the APOE*ε2 allele conferring a decreased risk relative to the common APOE*ε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE*ε4 carriers. The number of amyloid-β (Aβ)-dependent and Aβ-independent pathways that are known to be differentially modulated by APOE isoforms is increasing. For example, evidence is accumulating that APOE influences tau pathology, tau-mediated neurodegeneration and microglial responses to AD-related pathologies. In addition, APOE4 is either pathogenic or shows reduced efficiency in multiple brain homeostatic pathways, including lipid transport, synaptic integrity and plasticity, glucose metabolism and cerebrovascular function. Here, we review the recent progress in clinical and basic research into the role of APOE in AD pathogenesis. We also discuss how APOE can be targeted for AD therapy using a precision medicine approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All these effects are consistent with reported roles of APOE4 in inflammation, synaptic impairment, MAPK1 signaling and downstream APP transcription, and early endosomes7,18.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 is associated with increased amyloid-β deposition, hyperphosphorylation and aggregation of tau, and accelerated cognitive decline4–7.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APOE4 polymorphism alters the accessibility of the lipid-binding region, which interferes with its cholesterol and lipid transport capacity7.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 is the strongest genetic determinant of late-onset AD, increasing risk in a gene dose-dependent manner, whereas APOE2 confers substantial protection 1 -5 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“having the APOE ɛ4 coding mutation(s) increases AD risk 3–15 fold [3]”
From Association of SPI1 haplotypes with altered SPI1 gene expression and Alzheimer’s disease risk (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These include PLCG2 P522R rare variant (rs72824905) that provides robust protection against AD (odds ratio ≈ 0.68 [1, 4], comparable to having one APOE2 allele [5]”
From PLCγ2 deficiency compromises systemic immune tolerance and erodes myelin homeostasis while enhancing oxidative metabolism in the mouse brain (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE is the most important risk factor for AD and contributes significantly to the risk of developing several other neurological and nonneurological disorders (18).”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single copy of the APOE-E4 allele confers a ∼ 3.7 times greater risk than the common variant, APOE-E3, whereas homozygous APOE-E4/E4 carriers have a ∼12-15 times greater risk for developing AD.”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE genotype is the strongest genetic risk factor for AD21, with APOE ε2 conferring protection from disease and APOE ε4 conferring higher risk, compared to the APOE ε3 allele”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with this, binding to LDLR is required by ApoE to perform its downstream effector function (50–52).”
From Secreted Apoe rewires melanoma cell state vulnerability to ferroptosis (2024) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genome-wide association studies have consistently implicated immune-related pathways in AD susceptibility, particularly those involving microglial function [21,22].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When activated, microglia, the resident immune cells of the central nervous system, play a central role in amyloid clearance, synaptic remodeling, and the regulation of inflammatory signaling within the brain [21].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APOE gene is a known genetic risk factor for neurodegeneration and cardiovascular disease (CVD) [1, 2].”
From Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE4 exacerbates amyloid pathology by promoting Aβ production and aggregation, and inhibiting Aβ clearance and degradation”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE4 aggravates the tau pathology via promoting tau phosphorylation, aggregation, propagation, and tau-mediated neurodegeneration”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 mediates and regulates the endocytosis of > 30 ligands, including apolipoprotein E (APOE) and amyloid-β (Aβ) [21–27]”
From LRP1 is a neuronal receptor for α-synuclein uptake and spread (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Compared with APOE3, the APOE4 isoform increases AD risk and theAPOE2 isoform reduces AD risk.166”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 isoform may affects the development and progression of AD through multiple different pathways in which inflammatory regulation plays crucial role.166”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“It is known that APOE is predominantly expressed in glial cells, particularly astrocytes and activated microglia, which play central roles in A β accumulation, clearance, and neuroin fl ammation 3,4 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Hyperphosphorylated forms of the microtubule-associated protein tau in neurons is a major hallmark of AD [2, 3].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Multiple cohort studies have demonstrated that the APOE ε4 allele is a major genetic risk factor for AD”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“while the three common isoforms (APOE2, APOE3, and APOE4) influence both amyloid‐β–dependent and independent pathways implicated in AD pathogenesis [1, 2].”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“APOE plays a crucial role in the pathophysiology of AD, particularly in relation to Aβ and tau.43,44”
From Association of rare APOE missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“Cerebrovascular dysfunction has been recognized as a major pathological process of AD”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
The cited source says what the claim attributes to it.
In the citing paper
“with ApoE4-positive cells showing reduced function (Rawat et al., 2019; Yamazaki et al., 2019).”
From ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism (2021) · cites this paper as Yamazaki et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“ApoE4 shows both loss-of-function and gain-of-toxic-function across various AD pathogenesis pathways (Yamazaki et al., 2019).”
From ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism (2021) · cites this paper as Yamazaki et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, cerebral glucose hypometabolism occurs in both the early stage of AD (Christian et al., 2020; Yamazaki et al., 2019) and epilepsy (McDonald et al., 2018; Patel, 2018).”
From APOE4 reduces hippocampal expression of phosphoglycerate kinase 1 and sodium potassium pump to enhance seizure susceptibility in mice (2026) · cites this paper as Yamazaki et al., 2019
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“We also found that LECs isolated from the meninges of 6-month-old 5xFAD mice showed significant changes in the expression of genes involved in processes such as exocytosis, phospholipase D signaling, and response to low-density lipoprotein (Extended Data Fig. 1f–k), suggesting that meningeal Aβ deposition might affect meningeal LECs early on through deleterious processes previously implicated in”
From Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“a specific ApoE4 fragment, ApoE4[Δ(166-299)], has previously been found to promote the cellular uptake of extracellular Aβ42 and resulted in increased oxidative stress [28], similar to the effect of L28P.”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“APOE is the most significant known risk factor for sporadic Alzheimer’s disease”
From APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases (2024) · cites this paper as Yamazaki et al., 2019
In the citing paper
“ApoE4 exhibits the strongest receptor binding and is considered a high-risk allele, while ApoE2 exhibits the weakest receptor binding and is considered protective (Yamazaki et al., 2019).”
From APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases (2024) · cites this paper as Yamazaki et al., 2019
In the citing paper
“APOE also affects tau pathogenesis and tau-mediated neurodegeneration [468].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [468]
In the citing paper
“In fact, 39 AD-associated genes were found within the 10th percentile of highly expressed genes in meningeal LECs, including Apoe, which is intrinsically linked to altered risk for late onset AD15,31 and was one of the few highly expressed genes found at the intersection between all three cell types (Extended Data Fig. 9o).”
From Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Self-citation
Cited by
Sorted by citations
Items 201–300 of 1,006
Wang, S., Li, B., Li, J., Cai, Z., Hugo, C., Sun, Y. E., Qian, L., Julia, T. C. W., Chui, H. C., Dikeman, D., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00802-7 · Cited by 55
Yang, K., Zeng, C. C., Wang, C., Sun, M., Yin, D., & Sun, T. (2020) · Molecules · doi:10.3390/molecules25225439 · Cited by 49
The role of genetic risk factors of Alzheimer’s disease in synaptic dysfunction
Fu, W.-Y., & Ip, N. Y. (2023) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.07.011 · Cited by 48
Mishra, A., Wang, Y., Yin, F., Vitali, F., Rodgers, K. E., Soto, M., Mosconi, L., Wang, T., & Brinton, R. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101542 · Cited by 48
Wang, L., Shui, X., Diao, Y., Chen, D., Zhou, Y., & Lee, T. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216259 · Cited by 49
Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease
Zhang, T., Kim, B. M., & Lee, T. H. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-023-00395-5 · Cited by 49
Rao, A. T., Chen, N., Kim, M. J., Blumenfeld, J. R., Yip, O., Liang, Z., Shostak, D. M., Hao, Y., Nelson, M. R., Koutsodendris, N., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.10.005 · Cited by 48
Oberlin, L. E., Wan, L., Kang, C., Romano, A., Aghjayan, S. L., Lesnovskaya, A., Ripperger, H. S., Drake, J. A., Harrison, R., Collins, A. M., et al. (2024) · British Journal of Sports Medicine · doi:10.1136/bjsports-2024-108257 · Cited by 54
NLRP3 inflammasome in Alzheimer’s disease: molecular mechanisms and emerging therapies
Li, Z., & Gong, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1583886 · Cited by 53
Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers
Kreiser, R. P., Wright, A. K., Block, N. R., Hollows, J. E., Nguyen, L. T., LeForte, K., Mannini, B., Vendruscolo, M., & Limbocker, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228651 · Cited by 48
One-carbon epigenetics and redox biology of neurodegeneration
Coppedè, F. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.12.002 · Cited by 48
Wang, Z.-H., Xia, Y., Liu, P., Liu, X., Edgington‐Mitchell, L. E., Lei, K., Yu, S. P., Wang, X., & Ye, K. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102032 · Cited by 48
El-Fatah, I. M. A., Abdelrazek, H. M. A., Ibrahim, S. M., Abdallah, D. M., & El-Abhar, H. S. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105082 · Cited by 48
Wang, Z.-H., Xia, Y., Wu, Z., Kang, S. S., Zhang, J.-C., Liu, P., Liu, X., Song, W., Huin, V., Dhaenens, C., et al. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102212 · Cited by 48
Apolipoprotein E4 has extensive conformational heterogeneity in lipid-free and lipid-bound forms
Stuchell-Brereton, M. D., Zimmerman, M. I., Miller, J. J., Mallimadugula, U. L., Incicco, J. J., Roy, D., Smith, L. G., Cubuk, J., Baban, B., DeKoster, G. T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2215371120 · Cited by 48
Amyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease
Campos‐Peña, V., Pichardo-Rojas, P. S., Sánchez-Barbosa, T., Ortíz-Islas, E., Rodríguez-Pérez, C. E., Montes, P., Ramos-Palacios, G., Silva‐Adaya, D., Quintana, R. V., Cerna-Cortés, J. F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012092 · Cited by 47
Dehghani, S., Ocakcı, O., Hatipoglu, P. T., Özalp, V. C., & Tevlek, A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04825-5 · Cited by 49
NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load
Pohlkamp, T., Xian, X., Wong, C. H., Durakoglugil, M. S., Werthmann, G. C., Saido, T. C., Evers, B. M., White, C. L., Connor, J., Hammer, R. E., et al. (2021) · eLife · doi:10.7554/elife.72034 · Cited by 46
Random allelic expression in the adult human body
Kravitz, S. N., Ferris, E., Love, M. I., Thomas, A., Quinlan, A. R., & Gregg, C. J. (2023) · Cell Reports · doi:10.1016/j.celrep.2022.111945 · Cited by 46
Agnello, L., Piccoli, T., Vidali, M., Cuffaro, L., Sasso, B. L., Iacolino, G., Giglio, R. V., Lupo, F., Alongi, P., Bivona, G., et al. (2020) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2020.1740939 · Cited by 46
Coninx, E., Chew, Y. C., Yang, X., Guo, W., Coolkens, A., Baatout, S., Moons, L., Verslegers, M., & Quintens, R. (2020) · Aging · doi:10.18632/aging.104056 · Cited by 46
Insights on benzodiazepines' potential in Alzheimer's disease
Al-Kuraishy, H. M., Al-Gareeb, A. I., Alsayegh, A. A., Abusudah, W. F., Almohmadi, N. H., Eldahshan, O. A., Ahmed, E., & Batiha, G. E. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121532 · Cited by 45
Copper and cuproptosis: new therapeutic approaches for Alzheimer’s disease
Li, X., Chen, X., & Gao, X. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1300405 · Cited by 45
Duggan, M. R., Peng, Z., Sipilä, P. N., Lindbohm, J. V., Chen, J., Lü, Y., Davatzikos, C. A., Erus, G., Hohman, T. J., Andrews, S. J., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00682-4 · Cited by 47
Salvadó, G., Shekari, M., Falcón, C., Operto, G., Milà‐Alomà, M., Sánchez‐Benavides, G., Cacciaglia, R., Arenaza‐Urquijo, E. M., Niñerola‐Baizán, A., Perissinotti, A., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac134 · Cited by 45
Cholesterol Dysmetabolism in Alzheimer’s Disease: A Starring Role for Astrocytes?
Staurenghi, E., Giannelli, S., Testa, G., Sottero, B., Leonarduzzi, G., & Gamba, P. (2021) · Antioxidants · doi:10.3390/antiox10121890 · Cited by 44
Firdaus, Z., & Li, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042320 · Cited by 46
Apolipoprotein E Effects on Mammalian Ovarian Steroidogenesis and Human Fertility
Oriá, R. B., de Almeida, J. Z., Moreira, C. N., Guerrant, R. L., & Figueiredo, J. R. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.06.003 · Cited by 45
Brain Glymphatic/Lymphatic Imaging by MRI and PET
Lee, D. S., Suh, M., Sarker, A. K., & Choi, Y. (2020) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-020-00665-4 · Cited by 45
Crossing borders in Alzheimer’s disease: A T cell’s perspective
van Olst, L., Coenen, L., Nieuwland, J. M., Rodriguez-Mogeda, C., de Wit, N. M., Kamermans, A., Middeldorp, J., & de Vries, H. E. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114398 · Cited by 45
Wang, Q. S., Hasegawa, T., Namkoong, H., Saiki, R., Edahiro, R., Sonehara, K., Tanaka, H., Azekawa, S., Chubachi, S., Takahashi, Y., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01896-3 · Cited by 43
APOEε4 potentiates amyloid β effects on longitudinal tau pathology
Ferrari-Souza, J. P., Bellaver, B., Ferreira, P. C. L., Benedet, A. L., Povala, G., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Soares, C., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00490-2 · Cited by 43
Lee, R., Kim, J.-H., Kim, W., Hwang, S., Choi, S.-H., Kim, J., Cho, I., Kim, M., & Nah, S.-Y. (2024) · Journal of Ginseng Research · doi:10.1016/j.jgr.2024.02.002 · Cited by 43
Wang, X., Chen, S., Xia, X., Du, Y., Wei, Y., Yang, W., Zhang, Y., Song, Y., Lei, T., Huang, Q., et al. (2024) · Advanced Materials · doi:10.1002/adma.202411061 · Cited by 43
Bashir, B., Gulati, M., Vishwas, S., Gupta, G., Dhanasekaran, M., Paudel, K. R., Chellappan, D. K., Anand, K., Negi, P., Singh, P. K., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102689 · Cited by 45
Multi-functional role of apolipoprotein E in neurodegenerative diseases
Islam, S., Noorani, A. A., Sun, Y., Michikawa, M., & Zou, K. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1535280 · Cited by 43
Lindbohm, J. V., Mars, N., Sipilä, P. N., Singh‐Manoux, A., Runz, H., FinnGen, Livingston, G., Seshadri, S. S., Xavier, R. J., Hingorani, A. D., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00293-x · Cited by 42
Intracellular Cholesterol TraffickingPreprint
Ikonen, E., & Olkkonen, V. M. (2023) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041404 · Cited by 42
Neuronal ApoE4 in Alzheimer’s disease and potential therapeutic targets
Zhang, L., Xia, Y., & Gui, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1199434 · Cited by 41
microRNA-132 regulates gene expression programs involved in microglial homeostasis
Walgrave, H., Penning, A., Tosoni, G., Snoeck, S., Davie, K., Davis, E., Wolfs, L., Sierksma, A., Mars, M., Bu, T., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106829 · Cited by 41
Yarbro, J. M., Han, X., Dasgupta, A., Yang, K., Liu, D., Shrestha, H. K., Zaman, M., Wang, Z., Yu, K., Lee, D. G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56853-3 · Cited by 41
Xiong, M., Wang, C., Gratuze, M., Saadi, F., Bao, X., Bosch, M. E., Lee, C., Jiang, H., Serrano, J. R., Gonzales, E. R., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00610-x · Cited by 41
Pezzoli, S., Giorgio, J., Martersteck, A., Dobyns, L., Harrison, T. M., & Jagust, W. J. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13438 · Cited by 42
Geng, J., Zhang, Y., Chen, H., Shi, H., Wu, Z., Chen, J., & Luo, F. (2023) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000001933 · Cited by 41
Talebi, M., Kakouri, E., Talebi, M., Tarantilis, P. Α., Farkhondeh, T., İlgün, S., Pourbagher‐Shahri, A. M., & Samarghandian, S. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1923479 · Cited by 41
Short leukocyte telomeres predict 25-year Alzheimer's disease incidence in non-APOE ε4-carriers
Hackenhaar, F. S., Josefsson, M., Adolfsson, A. N., Landfors, M., Kauppi, K., Hultdin, M., Adolfsson, R., Degerman, S., & Pudas, S. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00871-y · Cited by 41
Harnessing cerebral organoids for Alzheimer's disease research
Bubnys, A., & Tsai, L. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.10.003 · Cited by 41
Apolipoprotein E Genotype e2: Neuroprotection and Its Limits
Kim, H., Devanand, D. P., Carlson, S., & Goldberg, T. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.919712 · Cited by 42
Acute ACAT1/SOAT1 Blockade Increases MAM Cholesterol and Strengthens ER-Mitochondria Connectivity
Harned, T. C., Stan, R. V., Cao, Z., Chakrabarti, R., Higgs, H. N., Chang, C. C. Y., & Chang, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065525 · Cited by 41
High-density lipoprotein in Alzheimer's disease: From potential biomarkers to therapeutics
Jin, Y., Chifodya, K., Han, G., Jiang, W., Chen, Y., Shi, Y., Xu, Q., Xi, Y., Wang, J., Zhou, J., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.018 · Cited by 41
He, L., Loika, Y., Park, Y., Bennett, D. A., Kellis, M., Kulminski, A. M., & Initiative, A. D. N. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01263-4 · Cited by 41
Damotte, V., van der Lee, S. J., Chouraki, V. A., Grenier‐Boley, B., Simino, J. M., Adams, H. H. H., Tosto, G., White, C. C., Terzikhan, N., Cruchaga, C., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12333 · Cited by 40
Apolipoprotein E isoform-dependent effects on the processing of Alzheimer's amyloid-β
Chai, A. B., Lam, H. H. J., Kockx, M., & Gelissen, I. C. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158980 · Cited by 41
Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer’s Disease Treatment
Poor, S. R., Ettcheto, M., Cano, A. C., Sánchez‐López, E., Manzine, P. R., Olloquequi, J., Camins, A., & Javan, M. (2021) · Pharmaceuticals · doi:10.3390/ph14090890 · Cited by 41
Definitive roles of TOMM40-APOE-APOC1 variants in the Alzheimer's risk
Kulminski, A. M., Philipp, I., Shu, L., & Culminskaya, I. V. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.09.009 · Cited by 40
Wasielewska, J. M., Chaves, J. C. S., Johnston, R. L., Milton, L. A., Hernández, D., Chen, L., Song, J. H., Lee, W., Leinenga, G., Nisbet, R. M., et al. (2022) · Theranostics · doi:10.7150/thno.72685 · Cited by 41
APOE genotype determines cell-type-specific pathological landscape of Alzheimer’s disease
Li, Z., Martens, Y. A., Ren, Y., Jin, Y., Sekiya, H., Doss, S. V., Kouri, N., Castanedes-Casey, M., Christensen, T. A., Miller Nevalainen, L. B., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.02.017 · Cited by 39
Self-citationCrosstalk between bone and brain in Alzheimer's disease: Mechanisms, applications, and perspectives
Liu, Z., Liu, M., Xiong, Y., Wang, Y., & Bu, X. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13864 · Cited by 39
Jin, S., Chen, X., Tian, Y., Jarvis, R., Promes, V., & Yang, Y. (2023) · Nature Communications · doi:10.1038/s41467-023-40926-2 · Cited by 39
Ferguson, C. M., Hildebrand, S. R., Godinho, B. M. D. C., Buchwald, J. E., Echeverria, D., Coles, A. H., Grigorenko, A. P., Vangjeli, L., Sousa, J., McHugh, N., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13703 · Cited by 43
The vascular contribution of apolipoprotein E to Alzheimer’s disease
Chen, F., Zhao, J., Meng, F., He, F., Ni, J., & Fu, Y. (2024) · Brain · doi:10.1093/brain/awae156 · Cited by 39
The Role of HDL and HDL Mimetic Peptides as Potential Therapeutics for Alzheimer’s Disease
Chernick, D., Zhong, R., & Li, L. (2020) · Biomolecules · doi:10.3390/biom10091276 · Cited by 39
Mechanisms of neuronal survival safeguarded by endocytosis and autophagy
Overhoff, M., Bruyckere, E. D., & Kononenko, N. L. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15194 · Cited by 40
Role of neddylation in neurological development and diseases
He, X., Zhu, A., Feng, J., & Wang, X. (2021) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2112 · Cited by 39
Paes-Colli, Y., Aguiar, A. F. L., Isaac, A. R., Ferreira, B. K., Campos, R. M. P., Trindade, P. M. P., Reis, R. A. D. M., & Sampaio, L. D. S. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.917164 · Cited by 39
Influence of genetic and cardiometabolic risk factors in Alzheimer’s disease
Pasqualetti, G., Thayanandan, T., & Edison, P. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101723 · Cited by 39
Impact of apolipoprotein E isoforms on sporadic Alzheimer’s disease
Lozupone, M., & Panza, F. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.375316 · Cited by 38
More than just risk for Alzheimer’s disease: APOE ε4's impact on the aging brain
Palmer, J. M., Huentelman, M. J., & Ryan, L. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.06.003 · Cited by 39
Olloquequi, J., Díaz‐Peña, R., Verdaguer, E., Ettcheto, M., Auladell, C., & Camins, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136928 · Cited by 40
Alldred, M. J., Penikalapati, S. C., Lee, S. H., Heguy, A., Roussos, P., & Ginsberg, S. D. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02453-3 · Cited by 38
Low‐Dose Copper Exposure Exacerbates Depression‐Like Behavior in ApoE4 Transgenic Mice
Xu, J., He, K., Zhang, K., Yang, C., Nie, L., Dan, D., Liu, J., Zhang, C.-E., & Yang, X. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6634181 · Cited by 38
Marottoli, F. M., Trevino, T. N., Geng, X. H., Arbieva, Z. H., Kanabar, P. N., Maienschein‐Cline, M., Lee, J. C., Lutz, S. E., & Tai, L. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.668296 · Cited by 38
Karanth, S. D., Katsumata, Y., Nelson, P. T., Fardo, D. W., McDowell, J. K., Schmitt, F. A., Kryscio, R. J., Browning, S. R., Braithwaite, D., Arnold, S. M., et al. (2022) · Brain · doi:10.1093/brain/awac035 · Cited by 38
Reducing PDK1/Akt Activity: An Effective Therapeutic Target in the Treatment of Alzheimer’s Disease
Yang, S., Du, Y., Zhao, X., Wu, C., & Yu, P. (2022) · Cells · doi:10.3390/cells11111735 · Cited by 38
Jiang, W., Glaeser, J. D., Salehi, K., Kaneda, G., Mathkar, P. P., Wagner, A., Ho, R., & Sheyn, D. (2022) · iScience · doi:10.1016/j.isci.2022.104504 · Cited by 38
Mok, K. K., Yeung, S. H., Cheng, G. W., Ma, I. W., Lee, R. H., Herrup, K., & Tse, K. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15748 · Cited by 37
Yi, M., Zhang, C., Zhang, Z., Yi, P., Xu, P., Huang, J., & Peng, W. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5243453 · Cited by 37
Interactive rather than independent effect of APOE and sex potentiates tau deposition in women
Wang, Y., Pascoal, T. A., Therriault, J., Kang, M. S., Benedet, A. L., Savard, M., Tissot, C., Lussier, F. Z., Arias, J. F., Mathotaarachchi, S. S., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab126 · Cited by 37
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants
Bu, G. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00556-6 · Cited by 37
Self-citationD. Bruce, K., Tang, M., Reigan, P., & H. Eckel, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218338 · Cited by 36
Cheng, G. W.-Y., Mok, K. K.-S., Yeung, S. H.-S., Kofler, J., Herrup, K., & Tse, K.-H. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac054 · Cited by 36
Lee, H.-J., Ko, E., & Lee, S. (2023) · Journal of Global Scholars of Marketing Science · doi:10.1080/21639159.2023.2248154 · Cited by 36
Caselli, R. J., Knopman, D. S., & Bu, G. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12124 · Cited by 36
Self-citationBanerjee, S., Ghoshal, S., Clemence, G., DeMars, K. M., Yang, C., Niehoff, M. L., Nguyen, A. D., Jayanth, P., Hoelscher, B., Xu, F., et al. (2021) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-021-00076-5 · Cited by 36
Inflammasome activation in neurodegenerative diseases
Ravichandran, K. A., & Heneka, M. T. (2021) · Essays in Biochemistry · doi:10.1042/ebc20210021 · Cited by 37
Dysfunctional microglia and tau pathology in Alzheimer’s disease
Ayyubova, G. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0087 · Cited by 36
Numakawa, T., & Kajihara, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031596 · Cited by 35
Kim, D. S., Ko, B., Ryuk, J. A., & Park, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082900 · Cited by 35
Wang, Y., Grydeland, H., Roe, J. M., Pan, M., Magnussen, F., Amlien, I. K., Watne, L. O., Idland, A., Bertram, L., Gundersen, T. E., et al. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.12.008 · Cited by 35
Lipid Homeostasis and Its Links With Protein Misfolding Diseases
Vendruscolo, M. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.829291 · Cited by 35
'Fly-ing' from rare to common neurodegenerative disease mechanisms
Ma, M., Moulton, M. J., Lu, S., & Bellen, H. J. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.03.018 · Cited by 35
Iron and Targeted Iron Therapy in Alzheimer’s Disease
Wang, J., Fu, J., Zhao, Y., Liu, Q., Yan, X., & Su, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216353 · Cited by 35
Modulation of Microglial Function by ATP-Gated P2X7 Receptors: Studies in Rat, Mice and Human
Tewari, M., Michalski, S. A., & Egan, T. M. (2024) · Cells · doi:10.3390/cells13020161 · Cited by 36
Quevenco, F. C., Bergen, J. M. G. V., Treyer, V., Studer, S. T., Kagerer, S. M., Meyer, R., Gietl, A. F., Kaufmann, P. A., Nitsch, R. M., Höck, C., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00046 · Cited by 34
Cell Type Impacts Accessibility of mRNA to Silencing by RNA Interference
Ferguson, C. M., Echeverria, D., Hassler, M. R., Ly, S., & Khvorova, A. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.06.006 · Cited by 34
Centenarians as Models of Resistance and Resilience to Alzheimer’s Disease and Related Dementias
Andersen, S. L. (2020) · Advances in Geriatric Medicine and Research · doi:10.20900/agmr20200018 · Cited by 35
de Frutos‐Lucas, J., Frost, N. J., Erickson, K. I., Serrano, J. M., Maestú, F., Laws, S. M., & Brown, B. M. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101173 · Cited by 34
Proceedings from the Fourth International Symposium on σ-2 Receptors: Role in Health and Disease
Izzo, N. J., Colom‐Cadena, M., Riad, A., Xu, J., Singh, M., Abate, C., Cahill, M. A., Spires‐Jones, T. L., Bowen, W. D., Mach, R. H., et al. (2020) · eNeuro · doi:10.1523/eneuro.0317-20.2020 · Cited by 34
Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease
Pu, J., Jin, C., Wang, Z., Fang, Y., Li, Y., Xue, N., Zheng, R., Lin, Z., Yan, Y., Si, X., et al. (2021) · Movement Disorders · doi:10.1002/mds.28805 · Cited by 34
Dun, C., Zhang, Y., Yin, J., Su, B., Peng, X., & Liu, L. (2022) · Age and Ageing · doi:10.1093/ageing/afac010 · Cited by 34
Metadata
- Authors
- Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G.
- Affiliations
- Mayo Clinic in Florida (US)
- Corresponding author
- Bu, Guojun
- Venue
- Nature Reviews Neurology
- Published
- 2019-07-31
- Volume
- 15
- Issue
- 9
- Pages
- 501-518
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC7055192
- OpenAlex
- W2965401191
- Cited by
- 1,425
- References
- 318
- Citations by year
- 2026: 191 · 2025: 259 · 2024: 233 · 2023: 242 · 2022: 200 · 2021: 172 · 2020: 124 · 2019: 4
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (RF1AG051504, R01AG027924, R37AG027924, RF1AG057181, RF1AG046205, R01AG035355)
- National Institute of Neurological Disorders and Stroke (P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE ε4, Alzheimer's disease, APOE polymorphism, amyloid-beta, tau pathology, neurodegeneration, microglial activation, lipid transport, synaptic plasticity, glucose metabolism, cerebrovascular function, precision medicine
- MeSH terms
- Alzheimer Disease, Apolipoproteins E, Brain, Humans, Polymorphism, Genetic, Amyloid beta-Peptides, Genetic Predisposition to Disease, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
